Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.

Salleras L, Navas E, Torner N, Prat AA, Garrido P, Soldevila N, Domínguez A.

Hum Vaccin Immunother. 2013 Mar;9(3):707-11. Epub 2013 Jan 7.

2.

Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.

Navas E, Salleras L, Domínguez A, Ibáñez D, Prat A, Sentís J, Garrido P.

Vaccine. 2007 Apr 20;25(16):3233-9. Epub 2007 Jan 25.

PMID:
17324489
3.

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG.

Hum Vaccin Immunother. 2017 Apr 3;13(4):867-876. doi: 10.1080/21645515.2016.1251537. Epub 2016 Nov 18. Review.

4.

Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.

Salleras L, Navas E, Domínguez A, Ibáñez D, Prat A, Garrido P, Asenjo MA, Torner N.

Vaccine. 2009 May 26;27(25-26):3454-8. doi: 10.1016/j.vaccine.2009.01.053. Epub 2009 Feb 5.

PMID:
19200830
5.

Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.

Salleras L, Domínguez A, Pumarola T, Prat A, Marcos MA, Garrido P, Artigas R, Bau A, Brotons J, Bruna X, Català P, Carreras E, Cuadra D, Gatell A, Millet S, Oller J, Raga E.

Vaccine. 2006 Nov 10;24(44-46):6638-42. Epub 2006 Jun 6.

PMID:
16842892
6.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046. Epub 2008 May 6.

PMID:
18462851
7.

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.

Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA.

Hum Vaccin Immunother. 2014;10(5):1171-80. doi: 10.4161/hv.28221. Epub 2014 Mar 7.

8.

Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.

Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, Zimmerman RK.

Am J Prev Med. 2016 May;50(5):600-8. doi: 10.1016/j.amepre.2015.12.010. Epub 2016 Feb 8.

9.

Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI.

PLoS One. 2011;6(7):e22308. doi: 10.1371/journal.pone.0022308. Epub 2011 Jul 29.

10.

Health benefits, risks, and cost-effectiveness of influenza vaccination of children.

Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA.

Emerg Infect Dis. 2006 Oct;12(10):1548-58.

11.
12.
13.

Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial.

Yoo BK, Humiston SG, Szilagyi PG, Schaffer SJ, Long C, Kolasa M.

Vaccine. 2013 Apr 19;31(17):2156-64. doi: 10.1016/j.vaccine.2013.02.052. Epub 2013 Mar 13.

14.

Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.

Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M.

Lancet Infect Dis. 2015 Dec;15(12):1459-66. doi: 10.1016/S1473-3099(15)00249-2. Epub 2015 Sep 8.

PMID:
26362172
15.

Vaccines for seasonal and pandemic influenza.

Nichol KL, Treanor JJ.

J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8.

PMID:
17163383
16.

Cost-effectiveness of influenza vaccination of healthy children.

Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T.

Vaccine. 2006 Jun 5;24(23):4934-41. Epub 2006 Apr 7.

PMID:
16678945
17.

The comparative value of various employer-sponsored influenza vaccination clinics.

Zimmerman RK, Wiringa AE, Nowalk MP, Lin CJ, Rousculp MD, Mitgang EA, Lee BY.

J Occup Environ Med. 2012 Sep;54(9):1107-17. doi: 10.1097/JOM.0b013e3182677d34.

PMID:
22929797
18.

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.

Lambe T, Spencer AJ, Mullarkey CE, Antrobus RD, Yu LM, de Whalley P, Thompson BA, Jones C, Chalk J, Kerridge S, Hill AV, Snape MD, Pollard AJ, Gilbert SC.

Pediatr Infect Dis J. 2012 Jun;31(6):e86-91. doi: 10.1097/INF.0b013e318255e443.

PMID:
22466328
19.

Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy.

Myers ER, Misurski DA, Swamy GK.

Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S128-40. doi: 10.1016/j.ajog.2011.04.009. Epub 2011 Apr 15. Review.

PMID:
21640230
20.

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.

Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB.

Pediatrics. 2001 Aug;108(2):E24.

PMID:
11483834

Supplemental Content

Support Center